Early Cancer Detection

GRAIL, LLC — The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

Precision Medicine — Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnosis of Diseases – Oncology Populations

University of Houston — Detection of circulating tumor cells with UniPro

Cancer caused by Rare Genetic Mutations

Caris Pharmatech Studies — A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Caris Pharmatech Studies — A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Caris Pharmatech Studies — Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Caris Pharmatech Studies — A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

Caris Pharmatech Studies — A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Caris Pharmatech Studies — A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Caris Pharmatech Studies — A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

Caris Pharmatech Studies — A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Caris Pharmatech Studies — A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Caris Pharmatech Studies — IRONMAN Registry Sub-Study: PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Caris Pharmatech Studies — ***REFERRAL ONLY*** Brightline 2- A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

Caris Pharmatech Studies — ***REFERRAL ONLY*** An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Caris Pharmatech Studies — ***REFERRAL ONLY*** A Phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors

Caris Pharmatech Studies — ***REFERRAL ONLY*** A phase Ia/Ib, open-label, dose escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors.

Prostate Cancer

AstraZeneca Pharmaceuticals — § A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) §

Pfizer Inc. — Talapro-3: A Phase 3, Randomized, Double-blind, Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer

Liver Cancer

Genentech/La Roche — A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Genentech — A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Pateints with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Skin Cancer

Castle Biosciences — Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Castle Biosciences — Performance of DecisionDx® DiffDxTM-Melanoma in Pediatric Populations

Castle Biosciences — Evaluation of Clinical Outcomes in Patients with Cutaneous Melanocytic Lesions Tested with a Differential Diagnostic Gene Expression Assay

Blood/Bone Marrow Cancer

Loxo Oncology, Inc — A Phase 3 Open Label, Randomized Study of Pirtobrutinib (Loxo-305) versus Ibrutinib in Patients with Chronic Lymophocytic Leukemia/Small Lymphocytic Lymphoma

European Myeloma Network — A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Pancreatic Cancer

Baylor College of Medicine — PanCan Early Detection Initiative for Pancreatic Cancer

Dartnet Institute — Cancer Health Equity Patient-Reported Outcome Performance Measure for Preventative Screening and Counseling

Baylor College of Medicine — Effectiveness of Healthy Habits for Older Adults to Optimize Rehabilitation

MD Anderson Cancer Center — Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Rural program expansion)

Cleerly, Inc. — § A Randomized Comparison of Personalized Care Based on Coronary Artery Disease Staging Versus Usual Care for Primary Prevention of Cardiovascular Events §

Surgical Innovation Associates — The Safety and Effectiveness of DuraSorb® for Lower Pole Reinforcement in Patients Undergoing 2-Stage Breast Reconstruction

Dartnet Institute — Individualizing Treatment for Asthma In Primary Care

Dartnet Institute — A Multi-Center Observational Study: The RECOVER Post Acute Sequelae of SARS-CoV-2 (PASC) Pediatric Cohort Study

Baylor College of Medicine and University of Houston — Precision Medicine for Alzheimer’s Disease and Related Dementias

Baylor College of Medicine — U.S. POINTER: U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk

UTHealth — A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in combination with Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults with Ulcerative Colitis

Investigator Initiated — Evaluating the Safety and Effectiveness of Immediate Sequential Bilateral Cataract Surgery: A Comparative Study